European urology最新文献

{"title":"Congress Calendar","authors":"","doi":"10.1016/j.eururo.2024.12.011","DOIUrl":"10.1016/j.eururo.2024.12.011","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages e38-e39"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FGFR Inhibition in Urothelial Carcinoma","authors":"Roger Li ,&nbsp;Joshua Linscott ,&nbsp;James W.F. Catto ,&nbsp;Siamak Daneshmand ,&nbsp;Bishoy M. Faltas ,&nbsp;Ashish M. Kamat ,&nbsp;Joshua J. Meeks ,&nbsp;Andrea Necchi ,&nbsp;Benjamin Pradere ,&nbsp;Jeffrey S. Ross ,&nbsp;Michiel S. van der Heijden ,&nbsp;Bas W.G. van Rhijn ,&nbsp;Yohann Loriot","doi":"10.1016/j.eururo.2024.09.012","DOIUrl":"10.1016/j.eururo.2024.09.012","url":null,"abstract":"<div><h3>Background and objective</h3><div>The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with <em>FGFR3</em> alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of bladder cancer, and the challenges that remain.</div></div><div><h3>Methods</h3><div>Original articles relevant to FGFR inhibitors in urothelial cancer between 1995 and 2024 were systematically identified in the PubMed and MEDLINE databases using the search terms “FGFR” and “bladder cancer”. An international expert panel with extensive experience in FGFR inhibitor treatment was convened to synthesize a collaborative narrative review.</div></div><div><h3>Key findings and limitations</h3><div>Somatic <em>FGFR3</em> alterations are found in up to 70% of low-grade non–muscle-invasive bladder cancers; these activate downstream signaling cascades and culminate in cellular proliferation. Beyond a link to lower-grade/lower-stage tumors, there is little consistency regarding whether these alterations confer prognostic risks for cancer recurrence or progression. <em>FGFR3</em>-altered tumors have been linked to a non-inflamed tumor microenvironment, but paradoxically do not seem to impact the response to systemic immunotherapy. Several pan-FGFR inhibitors have been investigated in mUC. With the introduction of novel intravesical drug delivery systems, FGFR inhibitors are poised to transform the therapeutic landscape for early-stage UC.</div></div><div><h3>Conclusions and clinical implications</h3><div>With deepening understanding of the biology of bladder cancer, novel diagnostics, and improved drug delivery methods, we posit that FGFR inhibition will lead the way in advancing precision treatment of bladder cancer.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 110-122"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First and Second-line Treatments in Metastatic Renal Cell Carcinoma","authors":"Regina Barragan-Carrillo ,&nbsp;Eddy Saad ,&nbsp;Renee-Maria Saliby ,&nbsp;Maxine Sun ,&nbsp;Laurence Albiges ,&nbsp;Axel Bex ,&nbsp;Daniel Heng ,&nbsp;Arnaud Mejean ,&nbsp;Robert J. Motzer ,&nbsp;Elizabeth R. Plimack ,&nbsp;Thomas Powles ,&nbsp;Brian I. Rini ,&nbsp;Tian Zhang ,&nbsp;Toni K. Choueiri","doi":"10.1016/j.eururo.2024.10.019","DOIUrl":"10.1016/j.eururo.2024.10.019","url":null,"abstract":"<div><h3>Background and objective</h3><div>The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first- and second-line treatments on the basis of current evidence.</div></div><div><h3>Methods</h3><div>We critically evaluated systemic treatment strategies for mRCC. A comprehensive literature search was conducted in PubMed and Embase, alongside manual searches of guidelines and conference proceedings up to October 2024. A narrative review was performed to reach a consensus, with voting used to resolve differing opinions among authors.</div></div><div><h3>Key findings and limitations</h3><div>First-line treatment options include immune checkpoint inhibitor (ICI)-based combinations or tyrosine kinase inhibitors (TKIs). Four combination regimens have been approved internationally. Owing to the lack of head-to-head trials and standardized biomarkers, treatment decisions rely on factors such as International Metastatic RCC Database Consortium (IMDC) risk score, functional status, safety profiles, sarcomatoid features, use of immunosuppressive drugs, and need for immediate response. Despite advances, many patients will experience disease progression on ICI-based therapy, necessitating further treatment. The need for standardized second-line approaches remains unmet. TKIs, alone or with everolimus, show promising efficacy, while HIF2a inhibitors offer newer options with a favorable toxicity profile. Rechallenge with ICIs after early progression is not recommended.</div></div><div><h3>Conclusions and clinical implications</h3><div>For optimal mRCC treatment selection, clinicians must carefully balance efficacy, toxicity, and patient preferences, especially when transitioning between first- and second-line therapies, to provide individualized care.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 143-154"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Hall of Fame","authors":"","doi":"10.1016/j.eururo.2024.12.010","DOIUrl":"10.1016/j.eururo.2024.12.010","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages e23-e33"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial","authors":"Sumanta K. Pal ,&nbsp;Petros Grivas ,&nbsp;Shilpa Gupta ,&nbsp;Nazli Dizman ,&nbsp;Zeynep Zengin ,&nbsp;Begona P. Valderrama ,&nbsp;Alejo Rodriguez-Vida ,&nbsp;Florian Roghmann ,&nbsp;Elena Sevillano Fernandez ,&nbsp;Surena F. Matin ,&nbsp;Yohann Loriot ,&nbsp;Srikala S. Sridhar ,&nbsp;Guru Sonpavde ,&nbsp;Mark T. Fleming ,&nbsp;Seth P. Lerner ,&nbsp;Joaquim Bellmunt ,&nbsp;Viraj Master ,&nbsp;Abhishek Tripathi ,&nbsp;Kim Davis ,&nbsp;David van Veenhuyzen ,&nbsp;Siamak Daneshmand","doi":"10.1016/j.eururo.2024.03.023","DOIUrl":"10.1016/j.eururo.2024.03.023","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 271-274"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140773546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Thomas Robert, Ellie Tang, Jennifer Kervadec, Jeremy Zaworski, Michel Daudon, Emmanuel Letavernier. Kidney Injury and Hair-straightening Products Containing Glyoxylic Acid. N Engl J Med 2024;390:1147–9","authors":"Chika Edward Uzoigwe","doi":"10.1016/j.eururo.2024.08.008","DOIUrl":"10.1016/j.eururo.2024.08.008","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Page e37"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141997097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceuticals in Genitourinary Cancers: A Fast-evolving Field with a Bright Perspective","authors":"Irene A. Burger ,&nbsp;John Babich","doi":"10.1016/j.eururo.2024.11.004","DOIUrl":"10.1016/j.eururo.2024.11.004","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 140-142"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma","authors":"Vadim S. Koshkin ,&nbsp;Guru P. Sonpavde","doi":"10.1016/j.eururo.2024.11.001","DOIUrl":"10.1016/j.eururo.2024.11.001","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 123-124"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection","authors":"Karim A. Touijer ,&nbsp;Emily A. Vertosick ,&nbsp;Daniel D. Sjoberg ,&nbsp;Nicole Liso ,&nbsp;Sunny Nalavenkata ,&nbsp;Barbara Melao ,&nbsp;Vincent P. Laudone ,&nbsp;Behfar Ehdaie ,&nbsp;Brett Carver ,&nbsp;James A. Eastham ,&nbsp;Peter T. Scardino ,&nbsp;Andrew J. Vickers","doi":"10.1016/j.eururo.2024.10.006","DOIUrl":"10.1016/j.eururo.2024.10.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>Lymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated BCR rates and compare rates of metastasis between the study arms.</div></div><div><h3>Methods</h3><div>Between October 2011 and March 2017, 1432 patients undergoing radical prostatectomy were enrolled at a single center. Surgeons were cluster randomized to perform limited (external iliac nodes) or extended PLND (external iliac, obturator, and hypogastric nodes) with crossover for 3-mo periods. Cox proportional-hazards regression with robust standard errors clustered by surgeon was used to assess whether the PLND template affected BCR or distant or locoregional metastasis.</div></div><div><h3>Key findings and limitations</h3><div>There were 452 BCR events at median follow-up of 4.2 yr for participants who did not develop BCR. The results confirm our previous finding of comparable BCR rates between the arms (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.97–1.13; <em>p</em> = 0.3). However, with 123 metastasis events and median follow-up of 5.4 yr for patients without metastasis, we found a clinically and statistically significant protective effect of extended PLND against metastasis (any metastasis: HR 0.82, 95% CI 0.71–0.93; <em>p</em> = 0.003; distant metastasis: HR 0.75, 95% CI 0.64–0.88; <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusions and clinical implications</h3><div>Patients undergoing radical prostatectomy should receive extended PLND that includes the external iliac, obturator, and hypogastric nodes. Further research should examine biological mechanisms regarding the anatomic location of affected nodes. Trials of LND for other cancers are warranted and should consider our clinically integrated design.</div><div>This trial is registered on ClinicalTrials.gov as NCT01407263.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 253-260"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142536555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What’s in a Name? Why Words Matter in Advanced Prostate Cancer","authors":"William K. Oh ,&nbsp;Neeraj Agarwal ,&nbsp;Alan Bryce ,&nbsp;Pedro Barata ,&nbsp;Courtney Bugler ,&nbsp;Sigrid V. Carlsson ,&nbsp;Brad Cornell ,&nbsp;William Dahut ,&nbsp;Daniel George ,&nbsp;Stacy Loeb ,&nbsp;Bruce Montgomery ,&nbsp;David Morris ,&nbsp;Lorelei A. Mucci ,&nbsp;Aurelius Omlin ,&nbsp;Ganesh Palapattu ,&nbsp;Irbaz Bin Riaz ,&nbsp;Charles Ryan ,&nbsp;Martin W. Schoen ,&nbsp;Samuel L. Washington III ,&nbsp;Silke Gillessen","doi":"10.1016/j.eururo.2024.10.017","DOIUrl":"10.1016/j.eururo.2024.10.017","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 2","pages":"Pages 101-103"},"PeriodicalIF":25.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}